In an initial proof-of concept study (RELAZA-1) 20 patients with MDS or AML were treated with up to 4 cycles Aza as soon as the CD34+ donor chimerism dropped in peripheral blood below a threshold of 80%, while patients were still in hematological remission. The gene discussed is CD34; the disease is acute myeloid leukemia.